Total Funding
2
3
Total FundingSeries B raised
Growth Score 2 in past quarter
-6 pts
Heat Score 3 in past quarter
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
404032
HyperBranch Medical Technology develops and commercializes products for the traumatic or surgically-induced wound market.
John Conn: President & CEO & Bord of DirectorsPast Role: Eli Lilly, Responsible for the Restructuring of Operations
About the Company
HyperBranch Medical Technology, Inc., a medical device company, develops and markets products primarily for the traumatic or surgically induced wound market. It offers OcuSeal, a liquid ocular bandage for direct application on the surface of the eye to form an ocular bandage, thereby covering an opening in the eye and providing an immediate
protective barrier; and Adherus Dural Sealant, which is used as an aid in dural repair in cranial and spinal surgeries, such as the treatment of intracranial aneurysms, tumors, and spinal disc disease. The company also provides Adherus Hernia Mesh Fixation, a device used as a replacement for tacks, staples, sutures, and 'O' rings in hernia repair procedur...



